Here’s What Inogen, Inc.’s (NASDAQ:INGN) P/E Is Telling Us

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize!

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We’ll show how you can use Inogen, Inc.’s (NASDAQ:INGN) P/E ratio to inform your assessment of the investment opportunity. Inogen has a price to earnings ratio of 71.19, based on the last twelve months. That means that at current prices, buyers pay $71.19 for every $1 in trailing yearly profits.

Check out our latest analysis for Inogen

How Do I Calculate A Price To Earnings Ratio?

The formula for price to earnings is:

Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Or for Inogen:

P/E of 71.19 = $138.99 ÷ $1.95 (Based on the trailing twelve months to September 2018.)

Is A High P/E Ratio Good?

A higher P/E ratio means that investors are paying a higher price for each $1 of company earnings. That is not a good or a bad thing per se, but a high P/E does imply buyers are optimistic about the future.

How Growth Rates Impact P/E Ratios

Probably the most important factor in determining what P/E a company trades on is the earnings growth. When earnings grow, the ‘E’ increases, over time. That means unless the share price increases, the P/E will reduce in a few years. So while a stock may look expensive based on past earnings, it could be cheap based on future earnings.

It’s nice to see that Inogen grew EPS by a stonking 49% in the last year. And its annual EPS growth rate over 5 years is 66%. So we’d generally expect it to have a relatively high P/E ratio.

How Does Inogen’s P/E Ratio Compare To Its Peers?

The P/E ratio indicates whether the market has higher or lower expectations of a company. The image below shows that Inogen has a higher P/E than the average (45) P/E for companies in the medical equipment industry.

NasdaqGS:INGN Price Estimation Relative to Market, February 22nd 2019
NasdaqGS:INGN Price Estimation Relative to Market, February 22nd 2019

Inogen’s P/E tells us that market participants think the company will perform better than its industry peers, going forward. Clearly the market expects growth, but it isn’t guaranteed. So investors should always consider the P/E ratio alongside other factors, such as whether company directors have been buying shares.

Remember: P/E Ratios Don’t Consider The Balance Sheet

It’s important to note that the P/E ratio considers the market capitalization, not the enterprise value. That means it doesn’t take debt or cash into account. Hypothetically, a company could reduce its future P/E ratio by spending its cash (or taking on debt) to achieve higher earnings.

Such spending might be good or bad, overall, but the key point here is that you need to look at debt to understand the P/E ratio in context.

Inogen’s Balance Sheet

Inogen has net cash of US$224m. That should lead to a higher P/E than if it did have debt, because its strong balance sheets gives it more options.

The Bottom Line On Inogen’s P/E Ratio

Inogen trades on a P/E ratio of 71.2, which is multiples above the US market average of 17.5. Its net cash position supports a higher P/E ratio, as does its solid recent earnings growth. Therefore it seems reasonable that the market would have relatively high expectations of the company

Investors have an opportunity when market expectations about a stock are wrong. As value investor Benjamin Graham famously said, ‘In the short run, the market is a voting machine but in the long run, it is a weighing machine.’ So this free visual report on analyst forecasts could hold the key to an excellent investment decision.

But note: Inogen may not be the best stock to buy. So take a peek at this free list of interesting companies with strong recent earnings growth (and a P/E ratio below 20).

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.